Compare REFR & TELA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | REFR | TELA |
|---|---|---|
| Founded | 1965 | 2012 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Multi-Sector Companies | Medical/Dental Instruments |
| Sector | Miscellaneous | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 33.6M | 37.5M |
| IPO Year | 1995 | 2019 |
| Metric | REFR | TELA |
|---|---|---|
| Price | $0.97 | $0.66 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 4 |
| Target Price | N/A | ★ $2.00 |
| AVG Volume (30 Days) | 26.0K | ★ 173.2K |
| Earning Date | 05-07-2026 | 05-07-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 37.59 |
| EPS | ★ N/A | N/A |
| Revenue | $1,488,642.00 | ★ $80,275,000.00 |
| Revenue This Year | N/A | $10.23 |
| Revenue Next Year | N/A | $14.26 |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | ★ 15.84 |
| 52 Week Low | $0.82 | $0.50 |
| 52 Week High | $2.70 | $2.19 |
| Indicator | REFR | TELA |
|---|---|---|
| Relative Strength Index (RSI) | 48.36 | 44.95 |
| Support Level | $0.90 | N/A |
| Resistance Level | $1.04 | $1.24 |
| Average True Range (ATR) | 0.06 | 0.13 |
| MACD | 0.01 | -0.00 |
| Stochastic Oscillator | 61.90 | 40.69 |
Research Frontiers Inc is engaged in the development and marketing of technology and devices to control the flow of light. The company develops and licenses its patented suspended particle device light-control technology to other companies that manufacture and market the SPD-Smart chemical emulsion, the light-control film made from the chemical emulsion, the light-control panels made by laminating the film, electronics to power end-products incorporating the film, or lamination services for, and the end-products. The company's revenue source comes from the licensing of technology.
TELA Bio Inc a commercial-stage medical technology company focused on providing innovative soft-tissue reconstruction solutions that optimize clinical outcomes by prioritizing the preservation and restoration of the patient's anatomy. Its growing product portfolio is purposefully designed to leverage the patient's natural healing response while minimizing long-term exposure to permanent synthetic materials. The company's OviTex portfolio consists of multiple product configurations intended to address various surgical procedures within hernia repair and abdominal wall reconstruction, including ventral, inguinal, and hiatal hernia repair.